The Future of the Paediatric Regulation
In 2017, the European Medicines Agency and the European Commission issued reports on the progress made in children’s medicines ten years after the Paediatric Regulation came into force. The legislation has had a considerable impact on the development and availability of medicines for children. However, it is clear that the system suffers from some weaknesses that need to be addressed in order to promote more innovation and development of high quality medicines for paediatric needs.
In view of the reports from EMA and the European Commission, we invite you to join us for our latest Women’s Life Sciences Network event featuring a discussion with:
Chief Legal Adviser
EU and International Coordinator
Danish Medicines Agency
We will discuss the findings in the paediatric reports and their potential legal and business impact on the life sciences industry.
The discussion will be followed by a networking reception with drinks and canapés.
We look forward to seeing you.
For more information, please contact Cristina Menendez Ruiz at +32 2 504 64 53 or at email@example.com.
Click here to join the Women’s Life Sciences Network LinkedIn Group.
All Women’s Life Sciences Network events are free of charge to participants and receive no funding from industry.